|Brand name(s), other common name(s)||Zolinza®|
|Drug type||Histone deacetylase inhibitor|
|How the drug is given||By mouth|
Vorinostat is FDA approved to treat cutaneous T-cell lymphoma (CTCL) in patients whose CTCL gets worse, does not go away or comes back after treatment with two systemic therapies.
Side effects needing medical attention:Blood clots in the legs (deep vein thrombosis); sudden swelling in a leg; pain or tenderness in the leg (the pain may only be felt when standing or walking); increased warmth in the area where the swelling is; skin redness or change in skin color; sudden, sharp chest pain; rapid pulse; fainting; cough with bloody secretions; feeling anxious; sweating; dehydration (loss of too much fluid from the body); low red blood cells; unusual bleeding or bruising under the skin; high blood sugar; paleness, shortness of breath and unusual tiredness.